Supplier: ProMab Technologies
Type of Product: Monoclonal Antibody
Description: BRAF(V-raf murine sarcoma viral oncogene homolog B1 ) is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439).B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK),it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers.The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi,primary cutaneous melanomas and colorectal cancers.
Application: ELISA: 1/10000; WB: 1/500 - 1/2000; IHC: 1/200 - 1/1000
Size: 100 ul, 1mg/ml
Species Reactivity: Human
Isotype: Mouse IgG1
Immunogen: Purified recombinant fragment of BRAF expressed in E. Coli.
Formulation: Ascitic fluid containing 0.03% sodium azide.
Storage: 4C; -20C for long term storage
Spplier link: http://www.promab.com/index.php?main_page=product_info&products_id=125
Reference: 1. Rapp, U.R.,et al.1983.Proc. Natl.Acad.Sci.USA.80:4218-4222. ; 2. Kim J,Giuliano AE,Turner RR.2006.Ann Surg.Nov, 244(5): 799-804. ; 3. Fullen DR, Poynter JN, Lowe L,2006.Mod Pathol. 19(10): 1324-1332. ; 4. Terai K, Matsuda M.2006.MBO J.25(15):3556-3564. ; 5. Noda H,Kato Y,Yoshikawa H,2006.J Exp Clin Cancer Res. 25(2):235-242. ;